Anti-TAU/ MAPT/ DDPAC monoclonal antibody

Anti-TAU/ MAPT/ DDPAC antibody for FACS & in-vivo assay

Target products collectionGo to MAPT/MAPT products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T45593-Ab-1/ GM-Tg-hg-T45593-Ab-2Anti-Human MAPT monoclonal antibodyHuman
GM-Tg-rg-T45593-Ab-1/ GM-Tg-rg-T45593-Ab-2Anti-Rat MAPT monoclonal antibodyRat
GM-Tg-mg-T45593-Ab-1/ GM-Tg-mg-T45593-Ab-2Anti-Mouse MAPT monoclonal antibodyMouse
GM-Tg-cynog-T45593-Ab-1/ GM-Tg-cynog-T45593-Ab-2Anti-Cynomolgus/ Rhesus macaque MAPT monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T45593-Ab-1/ GM-Tg-felg-T45593-Ab-2Anti-Feline MAPT monoclonal antibodyFeline
GM-Tg-cang-T45593-Ab-1/ GM-Tg-cang-T45593-Ab-2Anti-Canine MAPT monoclonal antibodyCanine
GM-Tg-bovg-T45593-Ab-1/ GM-Tg-bovg-T45593-Ab-2Anti-Bovine MAPT monoclonal antibodyBovine
GM-Tg-equg-T45593-Ab-1/ GM-Tg-equg-T45593-Ab-2Anti-Equine MAPT monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T45593-Ab-1/ GM-Tg-hg-T45593-Ab-2; GM-Tg-rg-T45593-Ab-1/ GM-Tg-rg-T45593-Ab-2;
GM-Tg-mg-T45593-Ab-1/ GM-Tg-mg-T45593-Ab-2; GM-Tg-cynog-T45593-Ab-1/ GM-Tg-cynog-T45593-Ab-2;
GM-Tg-felg-T45593-Ab-1/ GM-Tg-felg-T45593-Ab-2; GM-Tg-cang-T45593-Ab-1/ GM-Tg-cang-T45593-Ab-2;
GM-Tg-bovg-T45593-Ab-1/ GM-Tg-bovg-T45593-Ab-2; GM-Tg-equg-T45593-Ab-1/ GM-Tg-equg-T45593-Ab-2
Products NameAnti-MAPT monoclonal antibody
Formatmab
Target NameMAPT
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Diagnostic target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-MAPT benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-572Pre-Made Tilavonemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody
    BiosimilarGMP-Bios-ab-635Pre-Made Zagotenemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody
    BiosimilarGMP-Bios-ab-512Pre-Made Semorinemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody
    BiosimilarGMP-Bios-ab-061Pre-Made Bepranemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody
    BiosimilarGMP-Bios-ab-252Pre-Made Gosuranemab biosimilar, Whole mAb, Anti-MAPT Antibody: Anti-DDPAC/FTDP-17/MSTD/MTBT1/MTBT2/PPND/PPP1R103/TAU/tau-40 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species TAU/ MAPT/ DDPAC VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMAAV000031human MAPT AAV particle
    ORF Viral VectorpGMLV000202human MAPT Lentivirus plasmid
    ORF Viral VectorpGMAAV000031human MAPT AAV plasmid
    ORF Viral VectorvGMLV000202human MAPT Lentivirus particle
    ORF Viral VectorpGMLPm004846mouse Mapt Lentivirus plasmid
    ORF Viral VectorvGMLPm004846mouse Mapt Lentivirus particle


    Target information

    Target IDGM-T45593
    Target NameMAPT
    Gene ID4137,17762,29477,574327,480488,101089557,281296,100054638
    Gene Symbol and SynonymsDDPAC,FTDP-17,MAPT,MAPTL,MAPT_0N4R,MSTD,Mtapt,MTBT1,MTBT2,PHF-tau,PPND,PPP1R103,pTau,RNPTAU,TAU,tau-40,Tau-PHF6
    Uniprot AccessionP10636,P19332,P57786,P29172
    Uniprot Entry NameTAU_HUMAN,TAU_MACMU,TAU_RAT,TAU_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Diagnostics Biomarker, INN Index
    DiseaseBreast Cancer
    Gene EnsemblENSG00000186868
    Target ClassificationN/A

    The target: MAPT, gene name: MAPT, also named as DDPAC, FTDP-17L, MSTD, MTBT1, MTBT2, PPND, PPP1R103, TAU, MAPT. This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.